CLEC4OP: A Non-Protein-Coding RNA Molecule with Potential as a Drug Target

Target Name: CLEC4OP

NCBI ID: G102724279

CLEC4OP

Other Name(s): Long intergenic non-protein coding RNA 1835 | LINC01835 | C-type lectin domain family 4 member O, pseudogene | CLEC4O | Uncharacterized protein LOC102724279

CLEC4OP: A Non-Protein-Coding RNA Molecule with Potential as a Drug Target

CLEC4OP (Long intergenic non-protein coding RNA 1835) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a transcribed RNA molecule that is generated from a non-protein coding gene located between the intron and the 5' end of the gene.

CLEC4OP is unique because of its length, which is over 200 nucleotides. This is significantly longer than most non-coding RNAs, which are typically around 20 to 50 nucleotides in length. The extra length of Clec4op may allow it to have more extensive interactions with protein molecules and facilitate its function as a biomarker or drug target.

Clec4op is expressed in many different organisms, including humans, and it has been shown to play a role in various cellular processes. For example, Clec4op has been shown to be involved in cell adhesion, migration, and the regulation of gene expression. It has also been shown to interact with proteins that are involved in the development and progression of cancer.

One of the key reasons for the interest in Clec4op as a drug target is its potential to modulate the activity of other proteins. By interacting with known drug targets, Clec4op may be able to influence the activity of these targets and improve the effectiveness of drugs. For example, Clec4op has been shown to interact with the protein PDGF-BB, which is involved in the development and progression of cancer. By modulating the activity of PDGF-BB, Clec4op may be able to inhibit its effects and potentially lead to a more effective treatment for cancer.

Another potential mechanism by which Clec4op could be used as a drug target is its role in cell signaling. Clec4op has been shown to play a role in the regulation of cellular signaling pathways, including the NF-kappa pathway. This pathway is involved in the regulation of cell growth, differentiation, and survival, and is a key factor in the development and progression of many diseases, including cancer. By modulating the activity of NF-kappa, Clec4op may be able to influence the behavior of cells and potentially lead to the development of new treatments for these diseases.

Clec4op has also been shown to be involved in the regulation of gene expression. This is an important function of RNA molecules, as the expression of genes is regulated in many different ways, including by the binding of RNA factors. Clec4op has been shown to play a role in the regulation of gene expression by interacting with the RNA factor HIF1?±. This interaction between Clec4op and HIF1?± may allow Clec4op to influence the activity of HIF1?± and potentially regulate gene expression.

In conclusion, Clec4op is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. Its unique length and extensive interactions with other proteins make it an attractive candidate for these roles. Further research is needed to fully understand the function of Clec4op and its potential as a drug target.

Protein Name: C-type Lectin Domain Family 4 Member O, Pseudogene

The "CLEC4OP Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CLEC4OP comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets